Trial · NCT03170271
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Benralizumab | General health perceptions | 12.92 | Standard Error 1.01 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Placebo | General health perceptions | 7.29 | Standard Error 1.34 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Benralizumab | Vitality | 12.04 | Standard Error 1.10 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Placebo | Vitality | 6.53 | Standard Error 1.44 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Benralizumab | Social functioning | 12.44 | Standard Error 1.34 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Placebo | Social functioning | 9.32 | Standard Error 1.75 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Benralizumab | Role limitations due to emotional problems | 8.23 | Standard Error 1.18 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Placebo | Role limitations due to emotional problems | 5.79 | Standard Error 1.55 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Benralizumab | Mental health | 5.57 | Standard Error 0.90 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Placebo | Mental health | 3.89 | Standard Error 1.18 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Benralizumab | Physical health component summary score | 6.09 | Standard Error 0.46 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Placebo | Physical health component summary score | 3.77 | Standard Error 0.60 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Benralizumab | Mental health component summary score | 2.87 | Standard Error 0.48 | Scores on a scale |
| Change From Baseline in Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24) | Placebo | Mental health component summary score | 1.99 | Standard Error 0.64 | Scores on a scale |
| Patient Global Impression of Severity (PGI-S): Responder Status at the EOT (Week 24) | Benralizumab | Improvement | 61.7 | Percentage of patients | |
| Patient Global Impression of Severity (PGI-S): Responder Status at the EOT (Week 24) | Placebo | Improvement | 53.5 | Percentage of patients | |
| Patient Global Impression of Severity (PGI-S): Responder Status at the EOT (Week 24) | Benralizumab | Important improvement | 45.5 | Percentage of patients | |
| Patient Global Impression of Severity (PGI-S): Responder Status at the EOT (Week 24) | Placebo | Important improvement | 38.0 | Percentage of patients | |
| Clinician Global Impression of Change (CGI-C) and Patient Global Impression of Change (PGI-C): Responder Status at the EOT (Week 24) | Benralizumab | CGI-C: Much improved | 52.9 | Percentage of patients | |
| Clinician Global Impression of Change (CGI-C) and Patient Global Impression of Change (PGI-C): Responder Status at the EOT (Week 24) | Placebo | CGI-C: Much improved | 35.2 | Percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03170271/results?page=2